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High mobility group (HMG) A1 proteins are subject to a number of post-translational modifica-
tions, which may regulate their function in gene transcription and other cellular processes. We
examined, by using mass spectrometry, the acetylation of HMGA1a and HMGA1b proteins
induced by histone acetyltransferases p300 and PCAF in vitro and in PC-3 human prostate cancer
cells in vivo. It turned out that five lysine residues in HMGA1a, i.e., Lys-14, Lys-64, Lys-66, Lys-70,
and Lys-73, could be acetylated by both p300 and PCAF. We further quantified the level of
acetylation by analyzing, with LC-MS/MS, the proteolytic peptides of the in vitro or in vivo
acetylated HMGA1 proteins where the unmodified lysine residues were chemically derivatized
with a perdeuterated acetyl group. Quantification results revealed that p300 and PCAF exhibited
different site preferences for the acetylation; the preference of p300 acetylation followed the order
of Lys-64Lys-70 Lys-66 Lys-14Lys73, whereas the selectivity of PCAF acetylation followed
the sequence of Lys-70Lys-73  Lys-64Lys-66  Lys-14. HMGA1b was acetylated in a very
similar fashion as HMGA1a. We also demonstrated that C-terminal phosphorylation of HMGA1
proteins did not affect the in vitro acetylation of the two proteins by either p300 or PCAF.
Moreover, we examined the acetylation of lysine residues in HMGA1a and HMGA1b isolated
from PC-3 human prostate cancer cells. Our results showed that all the above five lysine residues
were also acetylated in vivo, with Lys-64, Lys-66 and Lys-70 in HMGA1a exhibiting higher levels
of acetylation than Lys-14 and Lys-73. (J Am Soc Mass Spectrom 2007, 18, 1569–1578) © 2007
American Society for Mass SpectrometryHigh mobility group (HMG) proteins, comprisingthree families of structurally unrelated proteinsincluding HMGA, HMGB, and HMGN, are non-
histone chromosomal proteins that are thought to play
important roles in the assembly of chromatin and in the
regulation of transcription in higher eukaryotic cells [1].
HMGA1 proteins contain three independent DNA-
binding regions, called AT-hook motifs, which bind to
the minor groove of AT-rich DNA sequences both in
vitro and in vivo [1–3]. HMGA1a and HMGA1b, for-
merly known as HMG-I and HMG-Y, respectively, are
translated from the splicing variants of a single gene
(HMGA1) and they are identical in sequence except for
an 11-amino acid internal deletion in HMGA1b (Figure 1)
[4, 5]. Both HMGA1a and HMGA1b are recognized as
architectural transcription factors that up- or down-
regulate the transcriptional activity of a number of
human genes [6, 7]. Despite the structural similarities
between HMGA1a and HMGA1b, these two proteins
may have distinct biological functions [8 –10].
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doi:10.1016/j.jasms.2007.05.020Among the highly modified nuclear proteins, HMGA1
proteins adopt a number of post-translational modifica-
tions (PTMs) including acetylation, methylation, and
phosphorylation. Phosphorylation of HMGA1 proteins
was first detected by Lund et al. [11] i n Ehrlich ascites
cells. Further research revealed that HMGA1 proteins
were phosphorylated by several kinases such as cyclin-
dependent kinase 1 (previously known as cdc2 kinase)
[12, 13], protein kinase C (PKC) [14], and protein kinase
CK2 [15]. These phosphorylations attenuated the DNA
binding affinities of mammalian HMGA1a [14, 16, 17]
and HMGA1b [17, 18].
In addition to phosphorylation, methylation was also
detected in HMGA1 proteins [8, 19 –23]. Dimethylation
of both arginine and lysine residues in HMGA1a was
reported and it might be correlated with the metastatic
potential and apoptosis of cells [19 –21]. Recently, we
reported that Arg-25 in HMGA1a, but not in HMGA1b,
was both mono- and dimethylated in PC-3 human
prostate cancer cells, with the dimethylation being in
either symmetric or asymmetric form [24]. Importantly,
some of the above phosphorylation and methylation
were also found in HMGA1a and HMGA1b proteins
isolated from human breast cancer tissues [25].
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lation of HMGA1 proteins was also detected [8, 9, 19,
26 –28]. In this respect, Lys-64 and Lys-70 in HMGA1a
protein can be acetylated by CBP (CREB-binding
protein) and PCAF (p300/CBP-associated factor), re-
spectively [26, 27]. In addition, the acetylation at
these two sites conferred distinct biological outcomes;
the acetylation of Lys-64 destabilized the enhanceo-
some, whereas the acetylation of Lys-70 potentiated
transcription of interferon- gene by stabilizing the
enhanceosome and preventing the acetylation of
HMGA1a by CBP [26, 27]. Moreover, multiple acety-
lation sites in HMGA1 proteins from MCF-7 human
breast cancer cells have been suggested, though the
assignment of these modifications to specific lysine
residues was not made [8]. Very recently, we re-
ported that Lys-14 in HMGA1a and HMGA1b was
acetylated in PC-3 cells. We, however, were not able
to identify any acetylated peptides containing Lys-64
and/or Lys-70 from the tryptic digestion mixture of
HMGA1a [28].
Mass spectrometry is commonly used for the identi-
fication of PTMs in proteins [29, 30]. However, PTMs
often alter the ionization efficiency of the peptide being
modified and, as a consequence, the observed relative
abundances of ions corresponding to the modified and
unmodified forms of a peptide may not reflect accurately
the level of modification. This problem can be resolved by
using stable isotope-labeled proteins or peptides, which
are chemically identical to the naturally occurring proteins
or peptides [31–33]. Incorporation of non-radioactive
isotopes into peptides or proteins of interest can be
achieved either in cell culture [34, 35] or after the
extraction of peptides/proteins from cells or tissues
[36, 37]. In this regard, quantitative analysis of phos-
phorylation [38, 39], glycosylation [40, 41], and acetyla-
tion [42] has been reported.
Herein, we adopted the quantification method intro-
duced by Smith et al. [42], which was developed to
quantify the levels of acetylation at individual lysine
residues in the N-terminal tail of histone H4, and
examined systematically the sites and levels of acetyla-
tion of HMGA1 proteins induced by histone acetyl-
transferases p300 and PCAF in vitro. Because HMGA1
proteins isolated from cancer cells showed simulta-
neous acetylation and phosphorylation [28, 43], we
further assessed how C-terminal constitutive phosphor-
ylation affects the acetylation of the two proteins. More-
over, we investigated the acetylation of lysine residues
in HMGA1a and HMGA1b isolated from PC-3 human
Figure 1. The sequences of HMGA1a and HMGA1b. The acety-
lated lysine residues identified in this studywere highlighted in bold,
and peptides containing these lysine residues were underlined.prostate cancer cells.Experimental
Purification of HMGA1 Proteins
Full-length recombinant human HMGA1a and HMGA1b
proteins were overexpressed in E. coli BL21 DE3 pLysS
cells (Invitrogen, Carlsbad, CA) followed by extraction
with 5% perchloric acid (PCA) as reported previously
[44, 45]. Recombinant HMGA1 proteins were further
purified on an Agilent 1100 system (Agilent Technolo-
gies, Palo Alto, CA) by using a 4.6 250 mm C4 column
(Grace Vydac, Hesperia, CA). The flow rate was 1.0
mL/min, and a 60-min gradient of 5% to 50% CH3CN in
0.1% aqueous solution of trifluoroacetic acid (TFA) was
employed. The purified proteins were then quantified
by Bradford protein assay (Bio-Rad, Hercules, CA).
The HMGA1 proteins were also isolated from PC-3
human prostate cancer cells following previously de-
scribed procedures [24]. Briefly, the PC-3 cells were
cultured in F-12 media (ATCC, Manassas, VA) supple-
mented with 10% fetal bovine serum (Invitrogen) and
5% CO2 at 37 °C. Cells were harvested and homoge-
nized by sonication in the lysis buffer followed by PCA
extraction. The HMGA1 proteins were then isolated
from the PCA-soluble fractions by using HPLC with a
4.6  250 mm C4 column (Varian, Walnut Creek, CA).
In Vitro Phosphorylation of HMGA1 Proteins
by Protein Kinase CK2
Recombinant HMGA1a or HMGA1b (15 g) was incu-
bated with 600 U of protein kinase CK2 (New England
BioLabs, Beverly, MA) and 200 MATP at 37 °C for 1 h
in a 150-L reaction buffer supplied by the vendor. The
phosphorylated HMGA1 proteins were then isolated
from the reaction mixture by using HPLC on the
Agilent 1100 system with a 2.0  250 mm C4 column
(Phenomenex, Torrance, CA). The flow rate was 200
L/min, and a 40-min gradient of 5% to 40% CH3CN in
0.1% aqueous solution of TFA was employed. The
chromatogram was obtained by absorbance detection at
220 nm. Fractions containing phosphorylated HMGA1a
or HMGA1b were collected and subjected to MALDI-MS
analysis to confirm the phosphorylated products.
In Vitro Acetylation of HMGA1 Proteins
by p300 and PCAF
Recombinant and CK2-phosphorylated HMGA1 pro-
teins were acetylated by the HAT (histone acetyltrans-
ferase) domain of p300 (Upstate, Temecula, CA) or
PCAF (Upstate) at enzyme-to-substrate molar ratios of
1:20 and 1:30, respectively. The acetylation reactions
were carried out in the presence of 1.5 nmol acetyl CoA
in a HAT buffer (50 mM Tris-HCl, pH 8.0, 0.1 mM
EDTA, 1.0 mM dithiothreitol, and 10% glycerol) at 30 °C
for 1 h [46, 47].
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Chemical derivatization of unmodified lysine residues
in HMGA1a or HMGA1b was carried out by incubating
the protein with 50 L deuterated acetic acid and 10 L
deuterated acetic anhydride at room temperature for
14 h. Deuterated proteins were then dried in a Speedvac
concentrator and resuspended in 50 mM NH4HCO3
followed by enzymatic digestion with sequencing-grade
modified trypsin or Glu-C (Roche Applied Science, Indi-
anapolis, IN) at respective enzyme-to-substrate ratios of
1:25 and 1:10 at 37 °C overnight.
Mass Spectrometry
Matrix-assisted laser desorption/ionization (MALDI)-
MS measurements were performed on a QSTAR XL
quadrupole/time-of-flight (TOF) mass spectrometer
equipped with an o-MALDI ion source (Applied
Biosystems, Foster City, CA). Purified protein samples
were dissolved in an aqueous solution of 0.1% TFA, and
sample aliquots (0.5 L) were mixed with an equal
volume of -cyano-4-hydroxy-cinnamic acid (CHCA)
saturated in 50% CH3CN containing 0.1% TFA. The
mass accuracy in MS/MS mode was 10 to 30 ppm
with external calibration. The digested peptides were
desalted with C18 ZipTip (Millipore, Billerica, MA) and
mixed with an equal volume of CHCA matrix solution
before subjecting to mass spectrometric analysis.
Most LC-electrospray ionization-tandem mass spec-
trometry (LC-ESI-MS/MS) experiments were carried
out by coupling directly the effluent from a Zorbax
SB-C18 capillary column (0.5  150 mm, 5 m in
particle size, Agilent Technologies) to a Global Ultima
Q-TOF mass spectrometer (Micromass, UK). Sequential
elution of peptides was accomplished by using a 65-min
linear gradient of 2% to 50% acetonitrile in 0.1% formic
acid delivered by the Agilent 1100 capillary HPLC
pump at a flow rate of 6 L/min. The spray voltage was
3.32 V, and the desolvation and source-block tempera-
ture were maintained at 120 °C and 80 °C, respectively.
Nitrogen was used as the cone and desolvation gas,
while helium was used as the collision gas.
Some LC-ESI-MS/MS experiments were also per-
formed on an LTQ linear ion trap mass spectrometer
(Thermo-Electron Co., San Jose, CA). MS/MS experi-
ments were carried out in either the data-dependent
scan mode or the preselected ion mode with a relative
collision energy of 35%. The spray voltage was 4.5 kV,
and the temperature for the heated capillary was
275 °C.
Quantitative assessment of the levels of acetylation
was based on LC-MS/MS results acquired on the Q-
TOF mass spectrometer, which was set up to monitor
specifically the fragmentations of the protonated ions of
the three peptides housing the acetylated lysine resi-
dues. The quadruple mass filter before the TOF ana-
lyzer was set with an LM and HM resolution of 2.0
(arbitrary units), which was equivalent to a 10 to 15 m/zwindow for the transmission of precursor ions. The
large isolation width was chosen because it allowed for
the precursor ions of both the acetylated (with an H3-Ac
group) and the unacetylated forms (with a D3-Ac group
introduced by chemical derivatization, vide supra) of a
peptide to be selected for fragmentation. A potential
drawback of using a large isolation width lies in that it
may also allow for other ions with m/z values lying in
the chosen m/zwindow to be selected for fragmentation
and complicate the product-ion spectra. Nevertheless,
under these experimental conditions, almost all ions
found in the resulting MS/MS could be attributed to
form from the cleavages of the peptide under investi-
gation (vide infra).
Relative acetylation levels of lysine residues were
quantified by calculating the ratio of peak intensities for
the H3-Ac- and D3-Ac-labeled precursor or product
ions. In this respect, five to fourteen scans were aver-
aged to give the spectrum used for the quantitative
assessment of the level of acetylation.
Results
In Vitro Acetylation of Recombinant HMGA1a
and HMGA1b
CBP and its closely related p300 were discovered as
transcriptional coactivators for a number of sequence-
specific factors that integrate diverse signaling path-
ways [48]. These two proteins and their associated
factor PCAF have intrinsic histone acetyltransferase
activity [49, 50]. They can induce the acetylation of
lysine residues not only in histone proteins but also in
many other transcriptional factors including TFIIE and
TFIIF; thus, they are also known as factor acetyltrans-
ferases [51]. In addition, p300 has been implicated in
DNA repair processes because of its involvement in the
acetylation of many DNA repair-enzymes such as flap
endonuclease 1 (FEN1), DNA polymerase  (Pol), G/T
mismatch-specific DNA glycosylase (TDG) and DNA
glycosylases NEIL2 and OGG1 [52–55]. It has been
reported that p300 could acetylate both HMGN1 (for-
merly known as HMG-14) and HMGN2 (formerly
known as HMG-17) at multiple sites, whereas PCAF
could acetylate only HMGN2 with Lys-2 being the
predominant acetylation site [56, 57]. Moreover, Mun-
shi et al. [27] showed that the HAT domains of both
CBP and PCAF could acetylate HMGA1a proteins as
efficiently as histones in vitro and the preferential
acetylation sites were Lys-64 and Lys-70, respectively,
according to the in vitro acetylation of peptide seg-
ments of HMGA1 proteins.
To investigate thoroughly the in vitro acetylation of
human HMGA1a and HMGA1b, we first obtained the
recombinant proteins, subjected these two proteins to
in vitro acetylation reaction with p300 and PCAF, and
monitored the acetylated proteins by MALDI-MS. The
MALDI-MS results showed that both p300 and PCAF
could induce the acetylation of HMGA1 proteins and
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shown), which made it necessary to carry out further
experiments to locate the acetylation sites and to eval-
uate the levels of acetylation at individual modified
lysine residues.
To determine the acetylation sites in HMGA1a pro-
tein, we digested the acetylated proteins with trypsin
and subjected the digestion mixture to LC-MS/MS
analysis on an LTQ linear ion trap mass spectrometer.
LC-MS/MS results allowed us to detect both the acety-
lated (SSQPLASK14QEK) and unacetylated peptides
(SSQPLASK14QEK and SSQPLASK14) containing Lys-14
(spectra not shown), which is consistent with our pre-
vious in vivo study [28]. However, we were not able to
identify any peptides containing Lys-64 or Lys-70, and
these two residues were previously shown to be acety-
lated by CBP and PCAF, respectively [27].
Since the region harboring Lys-64 and Lys-70
is rich in lysine and arginine residues (Figure 1),
the tryptic peptides produced from this region of
HMGA1 proteins might be too small to be detected
by LC-MS/MS. Therefore, we digested the HMGA1
proteins with Arg-C, which can selectively cleave
the amide bonds on the C-terminal side of an arginine
residue except for the arginine followed by a proline.
Indeed, MALDI mass spectrum of the digestion mix-
ture of HMGA1 proteins revealed clearly the presence
of both acetylated and unacetylated forms of the pep-
tide GRPKGSKNKGAAKTR (data not shown). This
peptide, however, was still not detectable by ESI-
MS/MS analysis, which might be attributed to the
formation of highly charged ions of this peptide whose
m/z values were too low to be chosen for collisional
activation.
Although we could detect all the peptides containing
Lys-14, Lys-64, and Lys-70, it remained challenging to
have a reliable measurement of the level of acetylation
at individual lysines for the following reasons. First of
all, acetylation of lysine residues in a peptide can alter
the ionization efficiency of the peptide. Therefore, the
level of acetylation may not be reflected accurately by
the relative abundances of ions of the modified and
unmodified forms of the peptide. Second, because the
amide bond on the C-terminal side of an acetylated
lysine is no longer susceptible to trypsin cleavage, the
acetylation level for Lys-14 has to be calculated based
on the ratio of the relative abundance of acetylated
peptides (SSQPLASK14QEK) over the sum of the
abundances of the two peptides bearing unacetylated
Lys-14 (i.e., SSQPLASK14QEK and SSQPLASK14).
For such calculation, other than making an assump-
tion that acetylation of Lys-14 does not change the
ionization efficiency of a peptide, we also need to
assume that the two peptides with different length and
amino acid composition share the same ionization effi-
ciency. The deviation from the latter assumption will
again lead to inaccurate quantification. Third, although
GRPK61GSK64NK66GAAK70TR could be found in both
the modified and unmodified forms in the MALDI massspectrum, the MS/MS of this peptide did not allow us
to locate the acetylation sites owing to the poor quality
of the spectrum (spectrum not shown).
The above issues, however, can be resolved by
applying the quantification method introduced by
Smith et al. [42]. A s shown in Figure 2, we first treated
the acetylated HMGA1 proteins with deuterated ace-
tic anhydride and deuterated acetic acid, which lead
to the labeling of all unacetylated lysine residues with
a deuterated acetyl moiety. The mass difference be-
tween a protiated acetyl group (H3-Ac, 42 Da) and a
deuterated acetyl group (D3-Ac, 45 Da) is 3 Da, making
it possible to distinguish between the enzyme- and
derivatization-induced acetylation. With this chemical
Figure 2. An outline of the experimental approach employed to
quantify the in vitro and in vivo acetylation of HMGA1a and
HMGA1b. HMGA1 proteins were treated with deuterated acetic
anhydride and deuterated acetic acid for 14 h. As a result, each of
the unacetylated lysine residues was conjugated with a deuterated
acetyl group. Digesting the proteins with trypsin or Glu-C pro-
duced the desired peptides in which the acetylated lysine residue
(either endogenously acetylated in PC-3 cells or in vitro acetylated
by p300 or PCAF) was tagged with a protiated acetyl moiety
(H3-Ac) and the unacetylated lysine residue was attached with a
deuterated acetyl group (D3-Ac). Since the mass difference be-
tween H3-Ac and D3-Ac is 3 Da, the acetylation level can be
determined from the ratio of the abundance of ions bearing H -Ac3
over the sum of those bearing H3-Ac and D3-Ac.
1573J Am Soc Mass Spectrom 2007, 18, 1569–1578 ACETYLATION OF HMGA1 PROTEINSderivatization, tryptic peptides containing an originally
unacetylated (now labeled with an Ac-D3) or acetylated
lysine will have the same length, owing to the inability
of trypsin to cleave the amide bond on the C-terminal
side of an acetylated lysine, and exhibit comparable
ionization efficiency, owing to the similar level of
change in ionization efficiency introduced by the addi-
tion of an Ac-D3 or an Ac-H3 to the lysine residue.
Another advantage of this approach lies in that deriva-
tization leads to a decrease in the charge state of
ESI-produced ions of peptides bearing multiple lysine
residues. With the above analysis in mind, the acetyla-
tion level for each lysine residue can then be calculated
from the ion abundance ratio of the protiated and
deuterated ions found in MS and/or MS/MS.
Following this approach, we identified five acety-
lated lysine residues (highlighted in bold italic in
Figure 1) residing in 3 peptides (underlined in Figure 1),
i.e., SSSKSSQPLASK14QE, GRPKGSK64NK66GAAK70TR,
and K73TTTTPGR, of the recombinant HMGA1a that
was acetylated in vitro by either p300 or PCAF. The
corresponding lysine residues in HMGA1b were
also acetylated by PCAF or p300. In this respect,
K73TTTTPGR and GRPKGSK64NK66GAAK70TR were
identified from the tryptic digestion mixture, whereas
SSSKSSQPLASK14QE was identified from the Glu-C
digestion mixture.
Here we began our discussion with the acetylation of
Lys-73. Figure 3 and Figure 4 depict the MS and
MS/MS, respectively, of the tryptic peptide K73TTTPGR
from HMGA1a that was acetylated in vitro by PCAF or
p300. The observed m/z values for the [M  2H]2 ions
of the protiated (m/z 452.3) and deuterated (m/z 453.8)
acetyl peptide is consistent with the calculated m/z
values. The relative abundances of the ions of m/z 452.3
and m/z 453.8 underscored that much higher level of
acetylation was induced by PCAF than by p300. Since
there is only one lysine residue in this peptide, the site
of acetylation can only be Lys-73, which was also
confirmed by MS/MS (Figure 4). The acetylation level
for Lys-73 can be quantified from either the relative
Figure 3. ESI mass spectra of tryptic peptide K73TTTTPGR from
HMGA1a acetylated by histone acetyltransferases PCAF (a) and
p300 (b).abundances of the acetylated (m/z 452.3) over unacety-
lated parent ion (m/z 453.8), or the corresponding ratios
for the b-series ions found in MS/MS (e.g., the b2 ion, as
shown in the insets on the left of Figure 4a and Figure 4b).
Results from triplicate measurements revealed that the
average percentages of acetylation induced by PCAF
and p300 were 68% and 11%, respectively, indicating
that Lys-73 in HMGA1a was more efficiently acetylated
by PCAF. In this context, it is worth noting that, under
our experimental conditions, we did not observe appar-
ent difference in the retention time for a peptide carry-
ing an H3-Ac and the corresponding peptide bearing a
D3-Ac functionality. In addition, we averaged all scans
collected in the whole elution time range for the peptide
under study to assess quantitatively the levels of acet-
ylation of lysine residues in this and other peptides.
To determine the levels of acetylation of Lys-64,
Lys-66, and Lys-70 in GRPKGSK64NK66GAAK70TR, we
subjected the tryptic digestion mixtures of p300- and
PCAF-acetylated HMGA1a to LC-MS and MS/MS anal-
ysis. The MS results for the digestion mixture of
HMGA1a acetylated by either p300 or PCAF revealed a
set of peaks corresponding to the triply charged ions of
the unacetylated, mono-, di-, and tri-acetylated peptides
(Figure 5). Although the MS data provided useful
information about the extent of acetylation of this
peptide, we have to rely on MS/MS to determine the
acetylation sites and the levels of acetylation of individ-
ual lysine residues in this peptide. In this respect, it is
worth noting that the window for the isolation of
precursor ions was chosen to be wide enough to accom-
modate all protiated and deuterated forms of the acety-
lated peptide.
In the product-ion spectra shown in Figure 6, both
the protiated and deuterated acetyl moieties were ob-
served to be present for y3, y4 and y6 ions but not for y2,
supporting that Lys-70 was partially acetylated by p300
or PCAF and the acetylation level could be determined
by the relative abundances of the protiated and deuter-
ated forms of the y3, y4, or y6 ion. Since the y6 ion was
more abundant than the y3 or y4 ion, the y6 ion was used
to calculate the acetylation level of Lys-70. We also
found that Lys-70 was acetylated more readily by PCAF
than by p300 (Figure 6, expanded spectra for y6 ion).
Moreover, the y7 and y8 ions exhibited higher abun-
dance ratios of protiated ion (acetylated) over deuter-
ated ion (unacetylated) than that of y6, suggesting that
Lys-66 was also acetylated by p300 and PCAF. The
acetylation level was determined based on the y7 and y6
ions using the equation described previously [42].
MS/MS results also support that Lys-61 in this peptide
was not acetylated because the b4 ion only carries the
D3-Ac-, but not the H3-Ac-labeled lysine. On the other
hand, we found that the b7 and b8 ions encompass both
the D3-Ac- and the H3-Ac-labeled lysine, supporting
that Lys-64 is acetylated. The percentage of acetylation
for this residue was determined from the b7 ion.
The peptides containing Lys-14 was not detected
from LC-MS/MS analysis of the tryptic digestion mix-
e ma
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PCAF and derivatized with deuterated acetic acid and
deuterated acetic anhydride. On the grounds that only
the amide bonds on the C-terminal side of arginine
residues can be cleaved after all the lysine residues are
acetylated enzymatically or chemically, Lys-14 is ex-
pected to be present in the tryptic peptide harboring
residues 1-23, which might be somewhat too long for
LC-MS/MS identification. After inspecting the se-
quence of HMGA1 proteins, we chose to employ Glu-C
for the digestion, which gave rise to the peptide
SSSKSSQPLASKQE. MS/MS of the [M  2H]2 ion of
this peptide facilitates us to conclude that Lys-14 in this
peptide was acetylated and the acetylation level of this
residue can be calculated either based on the [M 
2H]2 ion found in the MS or appropriate fragment ions
(the ion y7 was chosen here due to its high abundance)
observed in MS/MS (Data not shown).
The quantitative results from triplicate measure-
ments for the acetylation levels of all five identified
Figure 4. Product-ion spectra of the ESI-produ
of HMGA1a that was acetylated by PCAF (a) or p
two groups of peaks, are the expanded mass spe
to the unacetylated and monoacetylated forms
(bottom), respectively. The symbol “Ac” design
histone acetyltransferases. The two insets on th
corresponding to the acetylated (H3-Ac) and una
the acetylation was induced by PCAF (top) or p
fragment ions of this peptide is shown above thlysine residues in HMGA1a and HMGA1b are summa-rized in Figure 7. It turned out that p300 and PCAF
exhibited different substrate specificity profiles. In par-
ticular, the preference of p300 acetylation followed the
order of Lys-64Lys-70  Lys-66  Lys-14Lys73,
whereas the selectivity of PCAF acetylation followed
the sequence of Lys-70Lys-73  Lys-64Lys-66 
Lys-14. On the other hand, the acetylation profiles of
HMGA1a and HMGA1b, induced by either PCAF or
p300, showed remarkable similarity, underlying that
acetylation might not play a role in the different func-
tional roles assumed by HMGA1a and HMGA1b.
The Effect of C-Terminal Phosphorylation on the
Acetylation of HMGA1 Proteins
Protein kinase CK2 is known to phosphorylate the
acidic C-terminal tail of HMGA1a proteins at Ser-102
and Ser-103 both in vitro and in vivo [15, 58], linking
intracellular signaling to phosphorylation events occur-
 2H]2 ions of tryptic peptide K73TTTTPGR
(b) in vitro. The two insets on the right, showing
f the parent ion m/z 452.3 (453.8), corresponding
his peptide induced by PCAF (top) and p300
ions bearing acetyl lysine residues induced by
t are the expanded mass spectra of the b2 ion,
ated (D3-Ac) forms of this product ion, in which








300ring in the nucleus [16]. Prior research demonstrated
(b).
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acetylated in vivo [28, 43], and it has been suggested
that HMGA1a proteins, like histones, may exhibit a
biochemical modification “code” that is associated with
the cellular functions of these two proteins [7, 9, 19].
Therefore, it is important to examine whether C-terminal
constitutive phosphorylation of HMGA1 induced by pro-
tein kinase CK2 may affect its acetylation. To this end, we
carried out the in vitro phosphorylation of HMGA1 pro-
teins with protein kinase CK2 [45] followed by in vitro
acetylation with histone acetyltransferases p300 and
PCAF. We then assessed the acetylation of the two pro-
teins by using the same strategy as discussed above, and it
turned out that the C-terminal phosphorylation did not
affect appreciably the acetylation of the HMGA1 proteins
(Figure 7).
Acetylation of HMGA1 Proteins Isolated from PC-
3 Cells
After identifying the sites and quantifying the levels of
acetylation in these two proteins induced by p300 and
PCAF in vitro, we set out to investigate whether these
lysine residues are also acetylated in vivo. To this end,
we purified the HMGA1a and HMGA1b proteins from
PC-3 human prostate cancer cells and assessed the
acetylation of these two proteins by using the same
experimental procedures as discussed above. Our results
illustrated that all five residues that are susceptible to
Figure 5. ESI mass spectra of tryptic peptide GR
by histone acetyltransferases PCAF (a) and p300acetylation in vitro were also detected to be acetylated invivo (Figure 8). I n this respect, less than 10% of Lys-14
and Lys-73 was acetylated in vivo, whereas the average
percentages of acetylation for Lys-70, Lys-64, and
Lys-66 in HMGA1a were 20%, 15%, and 12%, respec-
tively. In this regard, similar distribution in acetylation
levels was found for HMGA1b (Figure 8). The large
error bar for the extent of acetylation of Lys-51 in
HMGA1b could be due to the low intensity for the ion
used for quantifying the acetylation level of this residue.
Discussion
The specific and controlled acetylation of lysine resi-
dues in histones plays an important role in the modu-
lation of chromatin structure associated with transcrip-
tional activation [59, 60]. HMGA1 proteins, like histone
proteins, are susceptible to acetylation both in vivo and
in vitro [8, 26 –28], and acetylation represents one of the
prominent PTMs of HMGA1 proteins in living cells [1].
In the present study, we examined systematically
both the sites and the degrees of acetylation of HMGA1
proteins in vitro and in PC-3 cells by using a mass
spectrometry-based approach. In particular, we em-
ployed a chemical derivatization method, first intro-
duced by Smith and coworkers [42], for the quantification
of the levels of acetylation. There are three advantages of
this quantification strategy over other methods for
quantifying HMGA1a acetylation. First of all, peptides
bearing an unmodified lysine residues, after being
SK64NK66GAAK70TR from HMGA1a acetylatedPKGlabeled with deuterated acetyl moiety (D3-Ac), or an
.1576 Q. ZHANG ET AL. J Am Soc Mass Spectrom 2007, 18, 1569–1578acetylated lysine residues (H3-Ac) have very similar, if
not identical, ionization efficiencies. Second, chemical
acetylation decreased the charge state of electrospray-
produced ions of the digested peptides containing
multiple lysine residues, which made it possible to
detect GRPKGSK64NK66GAAK70TR by LC-ESI-MS and
MS/MS. Moreover, the D3-Ac-modified lysine intro-
duced by derivatization blocked the cleavage of the
amide bond on the C-terminal side of the modified
lysine residues in the same way as the H3-Ac-modified
lysine induced by p300 or PCAF. Therefore, tryptic
peptides bearing the originally unmodified and acety-
lated lysine residues share the same sequence, which
allows for the quantification of the acetylation level.
Third, this approach allowed for the quantification of
the levels of individual lysine residues in a peptide
carrying multiple acetylated lysines.
Several conclusions can be drawn from our quanti-
fication measurements. First, HMGA1a and HMGA1b
exhibited a strikingly similar pattern of acetylation
induced by either p300 or PCAF. In this regard, it was
suggested that HMGA1a and HMGA1b, despite their
structural similarity, may have distinct biological
functions [8, 10] and, as a result, may undergo
different posttranslational modifications [9, 20, 24]. To
Figure 6. Product-ion spectra of the ESI-pr
GRPKGSK64NK66GAAK70TR from HMGA1a tha
The four insets are the expanded mass spectra o
was induced by PCAF (top) and p300 (bottom).
of this peptide is shown above the mass spectraexplore any possible differences between HMGA1a andHMGA1b in acetylation, we investigated thoroughly
the p300- and PCAF-catalyzed in vitro acetylation of the
recombinant proteins and the recombinant proteins
phosphorylated by protein kinase CK2. All the results
suggested that both the sites and the levels of acetyla-
tion induced by p300 or PCAF were remarkably similar
for HMGA1a and HMGA1b. Second, p300 and PCAF
acetylated the HMGA1 proteins in vitro with different
profiles of site specificity. Previous in vitro acetylation
assay [27] suggested that, except for the major acetyla-
tion sites of Lys-64 induced by CBP and Lys-70 induced
by PCAF, many other lysine residues can also be
acetylated, especially by PCAF. We, however, detected
only five acetylation sites, which might be attributed to
the fact that protein substrates, rather than peptide
substrates, were employed to examine the site prefer-
ences of histone acetyltransferases in the present study.
Third, G/SK may not always be the consensus acetyla-
tion motif induced by p300 as previously reported [61].
Our in vitro acetylation data revealed that, among the
five lysine residues that were acetylated, only Lys-14
and Lys-64 reside in this motif. Moreover, Lys-6 is
located in this G/SK motif in HMGA1a and HMGA1b,
however, it was not acetylated by p300.
Our data also demonstrated that C-terminal phos-
ed [M  2H]2 ion of the tryptic peptide
s acetylated in vitro by PCAF (a) and p300 (b).
eft) and y7 (right) ions, in which the acetylation
heme summarizing the observed fragment ionsoduc
t wa
f y6 (l
A scphorylation of HMGA1 proteins did not exert obvious
1577J Am Soc Mass Spectrom 2007, 18, 1569–1578 ACETYLATION OF HMGA1 PROTEINSeffect on the acetylation of these two proteins induced
by p300 or PCAF. We reason that the acidic C-terminal
tail of HMGA1 proteins is somewhat remote from the
lysine residues that are to be acetylated and, therefore,
the incorporation of additional negative charge to the
C-terminal motif does not affect the access of p300 or
PCAF to the lysine residues to be acetylated.
We further demonstrated that all five lysine residues
in HMGA1 proteins that could be acetylated by p300
and PCAF in vitro were also acetylated in PC-3 human
prostate cancer cells. Reversible acetylation of Lys-64
and Lys-70 modulates the transcription of IFN- gene
by regulating the destabilization and formation, respec-
tively, of an enhanceosome on the promoter region of
the IFN- gene [26, 27]. Lys-64 and Lys-70 in HMGA1a
were found to be acetylated in nonmetastatic and
moderately metastatic breast cancer cells such as MCF-
7/Tet-off cells and HA7C cells, but not in highly meta-
static HA8A breast cancer cells [19]. In addition, Lys-14
in HMGA1 proteins was observed to be acetylated in
PC-3 [28] and HA7C cells [19], whereas the same
residue was monomethylated in HMGA1a in nonmeta-
static MCF-7/Tet-off cells. The biological implications
of the acetylation of these lysine residues remain to be
established.
Our quantification data revealed that HMGA1a and
HMGA1b shared a similar acetylation pattern in living
cells, indicating that acetylation was not responsible for
Figure 7. Histograms showing the fraction of in vitro acetylation
at Lys-14, Lys-64, Lys-66, Lys-70, and Lys-73 of recombinant
HMGA1a and phosphorylated HMGA1a (phos-HMGA1a) cata-
lyzed by both p300 and PCAF (top panel), and the fraction of in
vitro acetylation at Lys-14, Lys-53, Lys-55 Lys-59, and Lys-62 of
recombinant HMGA1b and phosphorylated HMGA1b (phos-
HMGA1b) catalyzed by both p300 and PCAF (bottom panel).the PTM-associated different functions of HMGA1a and
HMGA1b. In vitro acetylation results showed that
Lys-14 and Lys-64 were preferentially acetylated by
p300, whereas Lys-70 and Lys-73 were favorable acety-
lation sites induced by PCAF. On the grounds that
both Lys-64 and Lys-70 exhibited relatively high and
comparable levels of acetylation, we suspect that both
p300 and PCAF might be involved in the in vivo
acetylation of HMGA1 proteins in PC-3 cells, which
was consistent with the fact that both CBP and PCAF
co-immunoprecipitate with HMGA1 proteins [27].
However, we cannot exclude the possibility that
other acetyltransferases might also be involved in the
acetylation of HMGA1 proteins.
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